PRISM BioLab
Business Services · Japan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
26-1 Muraoka-higashi, Fujisawa Shi, Kana...Website
www.prismbiolab.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About PRISM BioLab
PRISM BioLab is a biotechnology company that specializes in drug discovery through its proprietary PepMetics Technology, which creates molecules that mimic α-helix or β-turn peptides. The company aims to transform previously undruggable targets into druggable ones, focusing on finding cures for challenging diseases. Their PepMetics Library contains over 20,000 compounds designed for screening difficult targets, making it a valuable resource in the drug discovery process. PRISM BioLab collaborates with various partners and is open to scientific discussions to advance their research and development efforts.Explore more
PRISM BioLab Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PRISM BioLab your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
PRISM BioLab, which may be a good buyer, showed buying intent in Masked Content Topic
Check if PRISM BioLab has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on PRISM BioLab recently announced quarterly report
Click to see if PRISM BioLab had a recent Job posting/layoffs
Funding: Get notified immidiatlly once PRISM BioLab has new funding data
Check out if PRISM BioLab is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at PRISM BioLab
Product Launch: Get notified when PRISM BioLab launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
PRISM BioLab is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PRISM BioLab is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PRISM BioLab.
PRISM BioLab financials insights
Gather financial insights about PRISM BioLab, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Series B
$15M
2024
Series C
$10.3M
PRISM BioLab Tech Stack
A closer look at the technologies used by PRISM BioLab
PRISM BioLab News & Media
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets
TOKYO, Dec. 17, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus...PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM...PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka; President and COO: Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirmed receipt of the milestone payment. PRISM and Ono have entered into a "Joint Research and Licensing Agreement" on April 25, 2024, (hereinafter "the Agreement") for drug discovery in the oncology fieldEisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding PRISM BioLab
Sign Up For FreeTo access detailed company insights
PRISM BioLab is a biotechnology company that specializes in drug discovery through its proprietary PepMetics Technology, which creates molecules that mimic α-helix or β-turn peptides. The company aims to transform previously undruggable targets into druggable ones, focusing on finding cures for challenging diseases. Their PepMetics Library contains... Read More
